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ABSTRACT
Mutations or deregulated expression of the components of the spliceosome can 
influence the splicing pattern of several genes and contribute to the development 
of tumors. In this context, we report that the spliceosome modulator sudemycin 
induces selective cytotoxicity in primary chronic lymphocytic leukemia (CLL) cells 
when compared with healthy lymphocytes and tumor cells from other B-lymphoid 
malignancies, with a slight bias for CLL cases with mutations in spliceosome-RNA 
processing machinery. Consistently, sudemycin exhibits considerable antitumor 
activity in NOD/SCID/IL2Rγ-/- (NSG) mice engrafted with primary cells from CLL 
patients. The antileukemic effect of sudemycin involves the splicing modulation 
of several target genes important for tumor survival, both in SF3B1-mutated and 
-unmutated cases. Thus, the apoptosis induced by this compound is related to the 
alternative splicing switch of MCL1 toward its proapoptotic isoform. Sudemycin 
also functionally disturbs NF-κB pathway in parallel with the induction of a spliced 
RELA variant that loses its DNA binding domain. Importantly, we show an enhanced 
antitumor effect of sudemycin in combination with ibrutinib that might be related to 
the modulation of the alternative splicing of the inhibitor of Btk (IBTK). In conclusion, 
we provide first evidence that the spliceosome is a relevant therapeutic target in CLL, 
supporting the use of splicing modulators alone or in combination with ibrutinib as a 
promising approach for the treatment of CLL patients.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most 
frequent adult leukemia in western countries. The tumor 
is characterized by the proliferation and progressive 
accumulation of distinctive mature clonal B lymphocytes in 
blood, bone marrow and lymphoid tissues. The prognosis of 
the patients is highly heterogeneous; while some show an 
indolent disease, others follow an aggressive course with a 
median survival of less than 4–5 years [1, 2]. These clinical 
differences are largely associated with the mutational status 
of the variable region of immunoglobulin heavy chain genes 
(IGVH), cytogenetic alterations and expression of ZAP-70, 
CD38 or CD49d [3, 4].
In the last years, whole-genome and exome 
sequencing have revealed the presence of novel recurrent 
somatic mutations with functional impact in CLL patients. 
These studies have uncovered genetic alterations that 
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tend to cluster in different pathways, including Notch 
signaling, RNA splicing and processing machinery, innate 
inflammatory response, Wnt signaling and telomere 
maintenance [5–8]. SF3B1 is among the most frequently 
mutated genes in CLL affecting up to 5–18% of patients 
[6, 8, 9]. This gene encodes a core component of the 
spliceosome, the machinery that catalyzes the removal of 
introns from precursor mRNAs and ensures the fidelity 
of the process. Consistent with the crucial role of this 
pathway in CLL, mutations in other genes of the mRNA 
splicing, processing and transport machinery are also 
found to be frequently mutated in CLL patients [10].
Clinically, SF3B1 mutations provide independent 
prognostic information from the other known CLL 
prognostic markers. Such mutations correlate with a more 
aggressive behavior of the disease, rapid tumor progression, 
poorer clinical outcome and shorter time to treatment as well 
as treatment refractoriness [6, 8, 9, 11–13]. Consistently, 
SF3B1 mutations are mostly subclonal events in CLL, and 
therefore likely involved in disease progression [14].
Besides mutations, overexpression of the components 
of the spliceosome has been found in cancer, as a result, 
targeting this machinery has been proposed as a relevant 
therapeutic target [15]. In this context, several bacterial 
natural products have been described that target SF3B1 
and modulate RNA splicing, including FR901464 and 
pladienolide B, which induce antitumor activity in different 
tumor types [16, 17]. Additionally, the pladienolide 
derivative E7107 entered clinical trials for solid tumors. 
However its development has been significantly hampered 
due to the structural complexity of the molecule [18, 19]. 
A novel set of totally synthetic analogs of FR901464, the 
sudemycins, have demonstrated cytotoxicity toward several 
human tumor models, including lymphoma, both in vitro 
and in xenograft models [20–22].
Therefore, the spliceosome is an important emerging 
target for CLL therapy that has recently been uncovered 
but remains to be significantly exploited. Herein, we 
evaluate for the first time the antitumor effect of the 
spliceosome modulator sudemycin in SF3B1-mutated and 
-unmutated CLL cells in the in vitro and in vivo settings. 
Moreover, we investigate the molecular mechanisms 
underlying the antitumor effect of sudemycin in these 
cells and explore the effects of its combination with the 
clinically relevant BTK inhibitor, ibrutinib.
RESULTS
Sudemycins induce selective cytotoxicity in 
CLL cells with enhanced response in cases with 
mutations in the splicing and RNA processing 
machinery
To evaluate sensitivity to sudemycins, tumor 
cells from 41 CLL patients (Table 1) were tested with 
sudemycin C and the new improved version sudemycin 
D1 [22]. Cytotoxicity was measured after incubation of 
CLL cells with 100, 250 and 500 nM of drugs for 24 hours 
(Figure 1A). Sudemycin C and D1 induced apoptosis in 
CLL cells in a dose-response fashion achieving a mean 
response of 45.2 ± 20.1% and 63.4 ± 15.3% at the highest 
dose, respectively. At 48 hours, the cytotoxic effect was 
enhanced and sudemycin-induced apoptosis reached 57.9 
± 24.8% and 73.3 ± 24.3% for C and D1 at 500 nM dose. 
As expected, sudemycin D1 demonstrated to be more 
effective than C in inducing CLL apoptosis at all the doses 
tested and both timepoints (***p < 0.001, Figure 1A).
In parallel, we investigated the selective cytotoxicity 
of these compounds for CLL tumor cells. For this purpose 
we exposed B and T lymphocytes from healthy donors 
as well as T cells from CLL patients to the highest dose 
(500 nM) of both drugs. As shown in Figure 1B, sudemycins 
were significantly less cytotoxic in normal T and B 
counterparts than in CLL cells (*p < 0.05, **p < 0.01). 
Similar results were obtained with 250 nM dose. Sudemycin 
D1 (250 nM) was selected for further experiments because 
it was more effective at inducing apoptosis than C and 
maintained high selectivity for CLL cells.
Next, we sought to determine whether other 
B-lymphoid malignancies were also responsive to 
sudemycin D1. Tumor cells from mantle cell lymphoma 
(MCL; n = 8), follicular lymphoma (FL; n = 4) and 
multiple myeloma (MM; n = 4) were exposed to 
sudemycin D1 for 24 hours (Supplementary Table S1) 
and cytotoxicity was compared to that of CLL cells. 
Apoptosis induction resulted to be significantly higher in 
CLL cells than in tumor cells from the other malignancies 
studied, indicating a particular sensitivity of CLL cells to 
sudemycin D1 (Figure 1C; *p < 0.05, **p < 0.01).
Finally, we carefully examined CLL samples 
according to the presence of SF3B1 mutations. In 
addition, we also considered mutations in genes from 
other components of the splicing and RNA processing 
machinery. Of 38 CLL cases, 14 were SF3B1-mutated, 
8 harbored mutations in other genes of the splicing and 
RNA processing machinery and 16 were unmutated for 
both conditions (Table 1). Interestingly, although all cases 
were particularly sensitive to sudemycin D1, the mutated 
SF3B1 CLL cells were more sensitive to the drug than 
the unmutated ones. Intriguingly, those cases with other 
mutations in splicing and RNA processing machinery 
genes were as sensitive as SF3B1-mutated cases to the 
spliceosome modulator (Figure 1D, *p < 0.05).
The number of CLL cells in the peripheral blood 
and spleen decreases in sudemycin D6-treated mice
In view of the significant in vitro antitumor activity 
of sudemycin, the drug was accessed for efficacy in NOD/
SCID/IL2Rγ-/- (NSG) mice engrafted with primary cells 
from CLL patients. For these studies sudemycin D6 was 
used, which exhibited exactly the same cytotoxicity as D1 
(data not shown) and had been optimized for in vivo activity 
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Table 1: Characteristics of CLL samples
Patient nº. Age at 
diagnosis
Gender* Binet/
Rai 
stage
Previous 
treatment#
%CD19/ 
CD5†
IgVH 
status‡
SF3B1 
status‡
SF3B1 
mutation
Other 
splicing-
RNA 
processing 
machinery 
gene 
mutations
Cytogenetic 
alterations 
(FISH)§
% 
Cytotoxicity 
Sudemycin 
D1 250nM 
(24 h)
CLL 1 56 F A/0 no 94 M UM no no 13q del 27.3
CLL 2 67 M A/0 no 94 M UM no no 13q del 49.3
CLL 3 44 M C/IV no 97 M UM no no 13q del 39.6
CLL 4 62 F A/0 no 96 M UM no no 11q del 0.0
CLL 5 59 M B/II no 95 M UM no no 13q del 0.2
CLL 6 61 M C/III no 96 UM UM no no 11q del 62.8
CLL 7 52 M B/II R-FCM; R-BDM 97 UM UM no no normal 68.9
CLL 8 71 M C/IV no 94 M UM no no 13q del 74.6
CLL 9 66 F A/0 no 84 M UM no no 13q del 13.6
CLL 10 37 M A/I Fludarabine 64 M UM no no normal 62.9
CLL 11 58 M B/II FCM 95 UM UM no no ND 62.1
CLL 12 63 M C/IV R-FCM 97 UM UM no no 13q del; 17p del 61.6
CLL 13 58 M A/0 no 95 M UM no no normal 21.8
CLL 14 51 M A/0 no 80 M UM no no 13q del; 11q del 13.7
CLL 15 74 M C/IV FC 93 UM UM no no normal 28.2
CLL 16 74 M B/II R-FCM 87 UM no ND normal 51.9
CLL 17 64 M B/II no 93 M UM no no trisomy 12 29.9
CLL 18 44 M C/IV no 98 UM no ND 13q del 80.0
CLL 19 78 M A/0 no 95 M UM no ND trisomy 12 80.6
CLL 20 47 M C/IV
2CdA; FCM; 
Campath; 
CHOP
93 ND M G742D no 13q del 72.5
CLL 21 49 M A/I
FCM; 
R-CHOP; 
R-FCM
92 UM M K700E no 13q del 31.5
CLL 22 71 M B/II no 93 UM M R625H no normal 60.3
CLL 23 70 M B/II no 95 UM M G742D no 13q del 60.3
CLL 24 63 M A/0 no 90 M M M757T no normal 75.9
CLL 25 70 F B/I FC 99 M M K700E no 11q del; 13q del 70.7
CLL 26 54 F B/I FCM; CHOP-like 89 UM M R625H no 11q del 45.2
CLL 27 47 M B/II FCM; CHOP 79 UM M K741N no normal 60.7
CLL 28 48 M B/II CHOP 88 UM M G742D no ND 89.8
CLL 29 45 M B/II CHOP; FCM 95 ND M G742D no ND 59.5
(Continued )
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and dosing [22]. CLL cells from SF3B1-unmutated and 
-mutated patients were intravenously inoculated via the tail 
in the mice (n = 6 per condition). Since the in vivo antitumor 
effect of sudemycin D6 had been shown to be very fast and 
already significant after 5 days of treatment [22], mice were 
treated with vehicle or sudemycin D6 (14 mg/kg) daily for 
4 days and sacrificed (Figure 2A). As shown in Figure 2B, 
sudemycin D6 was able to reduce the presence of CLL 
cells in the peripheral blood (PB) and spleen of the mice. 
Tumor cells reduction in the spleen was near 25 and 40% 
in SF3B1-unmutated and -mutated cases, respectively. The 
decrease of CLL cells in PB samples was about 50 and 40% 
Patient nº. Age at 
diagnosis
Gender* Binet/
Rai 
stage
Previous 
treatment#
%CD19/ 
CD5†
IgVH 
status‡
SF3B1 
status‡
SF3B1 
mutation
Other 
splicing-
RNA 
processing 
machinery 
gene 
mutations
Cytogenetic 
alterations 
(FISH)§
% 
Cytotoxicity 
Sudemycin 
D1 250nM 
(24 h)
CLL 30 53 F B/II Fludarabine; R-FCM 70 UM M K666E no
11q del; 13q 
del 76.5
CLL 31 56 M B/II Chlorambucil 99 UM M T663I no 13q del 33.8
CLL 32 56 M B/III no 95 M M E862K no 13qdel; trisomy 12 48.4
CLL 33 78 F B/II no 94 UM M H662D no 13qdel; 11q del 36.9
CLL 34 86 F A/0 no 87 UM UM no SRSF7 (U2 no SF3B1) trisomy 12 44.0
CLL 35 71 M A/0 no 97 UM UM no
XPO1 
(RNA 
transport)
normal 67.1
CLL 36 45 F B/II R-FCM 86 UM UM no
NXF1 
(RNA 
transport)
trisomy 12; 
17p del 37.4
CLL 37 78 M B/II no 95 UM UM no
DDX3X 
(RNA 
transport)
13q del 74.7
CLL 38 66 M C/IV no 95 M UM no
CPEB3 
(mRNA 
decay)
13q del 53.2
CLL 39 73 F A/0 no 97 M UM no
SMG7 
(mRNA 
decay)
normal 67.1
CLL 40 70 F A/I no 90 M UM no
CDC5L 
(Prp19 
complex)
ND 76.3
CLL 41 38 M A/0 no 98 M UM no
HELZ 
(RNA 
helicase), 
PIWIL3 
(RNA 
silencing)
13q del; 11q 
del 51.0
ND: not determined
*M: male; F: female.
†quantified by flow cytometry
‡UM: unmutated; M: mutated
§assessed by FISH. del: deletion
#R: Rituximab; FCM: Fludarabine, Cyclophosphamide, Mitoxantrone; BDM: Bendamustine; 2CdA: Cladribine; CHOP: 
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; FC: Fludarabine, Cyclophosphamide
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Figure 1: Sudemycins selective induction of cytotoxicity in CLL. A. Primary cells from CLL patients were incubated with the 
indicated doses of sudemycin C and D1 for 24 (n = 41) and 48 hours (n = 27). Cytotoxicity was quantified after annexin V/PI staining 
by flow cytometry and referred to the untreated control. Bars represent the mean ± SEM of all samples analyzed. ***p < 0.001. B. CLL 
cytotoxicity after sudemycin (500 nM) exposure for 24 hours was compared to that of B and T lymphocytes from healthy donors (n = 5) 
as well as T lymphocytes from CLL patients (n = 4). T and B lymphocytes were labeled and gated with anti-CD3-FITC and anti-CD19-PE 
antibodies. Mean ± SEM of all cases analyzed. *p < 0.05, **p < 0.01. C. Sudemycin D1-induced cytotoxicity (250 nM) was compared in 
CLL (n = 41), MCL (n = 8), FL (n = 4) and MM (n = 4) samples. Cell death was measured at 24 hours by flow cytometry and referred to the 
corresponding untreated cells. Mean ± SEM of all cases analyzed. *p < 0.05, **p < 0.01. D. Diagram representing cytotoxicity at 24 hours 
of sudemycin D1 (250 nM) in CLL samples classified according to the presence of SF3B1 or other mutations in splicing-RNA processing 
machinery genes (Unmutated, n = 16; SF3B1-mutated, n = 14; other mutations n = 8). Cytotoxicity was referred to the respective untreated 
control. *p < 0.05.
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for SF3B1-unmutated and -mutated cases, correspondingly. 
Altogether these results confirmed that sudemycin D6 was 
effective in this NSG/CLL xenograft model.
The apoptotic effect of sudemycin D1 is related 
to MCL1 alternative splicing
To assess the ability of sudemycin D1 to modulate 
spliceosome activity in CLL cells, we analyzed DNAJB1 
expression as a surrogate marker for RNA splicing 
modulation [16]. A 6-hour treatment was chosen to avoid 
unspecific events related to cell death induction. As shown 
in Figure 3A, we confirmed that a 6-hour sudemycin D1 
incubation increased the unspliced form of DNAJB1 that 
retained intron 2, both in SF3B1-unmutated and -mutated 
CLL samples.
Next, in order to characterize the cell death 
mechanisms of sudemycin D1-induced cytotoxicity, 
primary cells from SF3B1-unmutated and -mutated CLL 
cases were preincubated with the pan-caspase inhibitor 
Q-VD-OPh before drug treatment and apoptotic markers 
were analyzed by flow cytometry. As shown in Figure 3B, 
Q-VD-OPh efficiently blocked both caspase-3 activation 
and phosphatidylserine (PS) exposure, indicating that the 
apoptotic process was caspase-dependent. Interestingly, 
sudemycin D1 induced a marked downregulation of the 
antiapoptotic protein Mcl-1, which was not reverted by 
caspase-inhibitor treatment and thus not degraded by caspases 
(Figure 3C). Since MCL1 gene encodes the antiapoptotic 
Mcl-1-
LONG
 and the proapoptotic Mcl-1-SHORT proteins, and 
the Mcl-1-
LONG
/Mcl-1-SHORT balance is regulated by alternative 
splicing [23], we hypothesized that sudemycin D1-induced 
apoptosis might be related to the switch of the alternative 
splicing of MCL1 toward its proapoptotic short isoform. 
Using RT-PCR with specific primers for exon 1 and exon 3 
of MCL1, we showed that sudemycin D1 upregulated MCL1-
SHORT splice variant, which lacks exon 2, while decreasing 
MCL1-
LONG
, already at 30 minutes of treatment, both in 
SF3B1-unmutated and -mutated CLL cases (Figure 3D).
Sudemycin D1 induces RELA alternative 
splicing together with the inhibition of the  
NF-κB pathway
Among the prosurvival pathways in CLL, we were 
particularly interested in investigating whether sudemycins 
were able to modulate NF-κB signaling due to its critical 
role in CLL pathogenesis [24, 25].
First, gene expression of well-known protumor NF-
κB target genes (IL8, MMP9 and CCL4) was determined 
Figure 2: Effect of sudemycin D6 in an adoptive transfer model of CLL. A. CLL cells were inoculated via the tail in NSG mice. 
After 24 hours, mice were treated with vehicle or sudemycin D6 (14 mg/kg) daily during 4 days and sacrificed. B. PB and spleen samples 
were recovered and viable CLL cells in these compartments were counted by flow cytometry. Bars represent the mean ± SEM of SF3B1-
unmutated (n = 6 per group) and -mutated (n = 6 per group) cases.
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Figure 3: Sudemycin-induced MCL1 alternative splicing. A. RT-PCR analysis of spliced and unspliced DNAJB1 mRNAs. cDNA 
was obtained from sudemycin D1-treated CLL cells (250 nM) for 6 hours and RT-PCR was performed with primers spanning two exons; 
products were analyzed in a QIAxcel capillary electrophoresis device. B. Analysis of apoptosis in CLL samples exposed to sudemycin D1 
(250 nM; 24 hours) and/or the caspase inhibitor Q-VD-OPh (10 μM). Caspase 3 and PS exposure levels were quantified by flow cytometry 
by staining of cells with CellEvent caspase 3/7 green assay and annexin V-FITC, respectively. Bars represent the mean ± SEM of SF3B1-
unmutated (n = 4) and -mutated (n = 5) cases. *p < 0.05; **p < 0.01. C. Mcl-1 protein levels evaluated by western blot after sudemycin D1 
(250 nM; 24 hours) and/or Q-VD-OPh (10 μM) exposure in CLL primary cells. D. RT-PCR analysis of MCL1 splicing in sudemycin D1-
treated CLL cells (250 nM) for the indicated times. PCR was performed with primers binding exons 1 and 3, and products were analyzed 
in a QIAxcel capillary electrophoresis device.
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by quantitative RT-PCR. After a 6-hour exposure to 
sudemycin D1, a significant decrease in all NF-κB 
target genes was observed in both SF3B1-mutated and 
-unmutated CLL cases (*p < 0.05). SF3B1-mutated cases, 
showed a higher reduction of these targets than unmutated 
ones, suggesting that NF-κB modulation by sudemycin 
could, at least partially, explain the slight differences in 
sensitivity to sudemycin (Figure 4A).
To further explore the role of NF-κB on sudemycin 
activity, we stimulated the NF-κB pathway in CLL cells 
with CD40 ligand (CD40L) and interleukin 4 (IL4) 
soluble factors. Consistently, an about a 2-fold increase 
in phospho-p65 (p-p65) levels was detected after this 
stimulation. Sudemycin D1 demonstrated to overcome 
the prosurvival effects induced by CD40L and IL4 since 
it was as effective at inducing apoptosis as in control cells 
(Figure 4B).
Next, we focused on RELA (p65) because the 
functional effect of its alternative splice variants had 
been characterized. RELA exon 8 encodes for the Rel 
homology domain, which is required for dimerization and 
DNA binding [26]. In order to find whether this exon was 
lost by alternative splicing after sudemycin treatment, 
we analyzed by RT-PCR exons 7 to 10 from RELA. 
Indeed, an isoform lacking exon 8 and partially exon 7 (as 
confirmed by sequencing) was detected when CLL cells 
were exposed to a short incubation with sudemycin D1 in 
both SF3B1-mutated and unmutated cases (Figure 4C and 
Supplementary Information).
Finally, NF-κB activity was assessed in nuclear 
extracts from sudemycin-treated CLL cells both in SF3B1-
mutated and unmutated cases by means of the p65 DNA 
binding capacity. As shown in Figure 4D, 6-hour exposure 
to sudemycin D1 reduced NF-κB p65 activity by 20–30%, 
showing a moderate bias for the SF3B1-mutated when 
compared to the -unmutated CLL cases.
The combination of sudemycin D1 with ibrutinib 
results in an enhanced cytototoxic effect in 
parallel with IBTK splicing modulation
In CLL, the promising results at clinical level of 
the Btk inhibitor ibrutinib have motivated numerous trials 
in combination with chemotherapy or immunotherapy 
[27]. In order to find out a potential clinically 
relevant combination for sudemycin, we explored the 
combination with ibrutinib. For this purpose, primary 
CLL cells from SF3B1-unmutated and -mutated cases 
were simultaneously exposed to sudemycin D1 and the 
Btk inhibitor for 48 hours. Interestingly, the combination 
induced significantly more apoptosis than each drug 
alone both in mutated and unmutated CLL cases (Figure 
5A; *p < 0.05, **p < 0.01). Next, we postulated that Btk 
activity might be synergistically downmodulated with 
the drug combination. To test this, we analyzed activated 
phospho-Btk (pBtk) by flow cytometry. Surprisingly, 
sudemycin D1 induced a moderate increase of pBtk 
levels both in SF3B1-mutated and unmutated CLL cases 
(p = 0.06, marginally significant). As expected, the Btk 
inhibitor ibrutinib downregulated pBtk (*p < 0.05) while 
the levels of pBtk in the combination remained as low 
as ibrutinib alone (Figure 5B), indicating that ibrutinib 
blocked this undesired effect of sudemycin.
Ibtk is a physiological inhibitor of Btk and 
particularly its exon 25 encodes the region of the protein 
required for Btk binding [28, 29]. For this reason, we 
analyzed whether this exon could be lost by alternative 
splicing after sudemycin D1 exposure. Consistently, using 
an RT-PCR strategy to detect IBTK transcripts spanning 
exons 24 to 26, a band of lower molecular weight than 
the full isoform was amplified after incubation of CLL 
cells with sudemycin D1 for 6 hours. This shorter 
band corresponded to the isoform lacking exon 25 as 
confirmed by sequencing (Figure 5C and Supplementary 
Information). In contrast, ibrutinib alone did not induce 
this isoform, which was nevertheless generated with the 
drug combination (Figure 5D).
Altogether these results demonstrated that the 
combination of sudemycin D1 with ibrutinib resulted in 
an enhanced cytototoxic effect involving IBTK splicing 
modulation.
DISCUSSION
Mutations or misregulated expression of the 
components of the spliceosome can influence the splicing 
pattern of several genes and play a crucial role in the 
development of tumors. In this line, genes encoding the 
spliceosome have been reported to be frequently mutated 
or overexpressed in cancer [15, 30, 31]. In CLL, SF3B1 
mutations have emerged as one of the most frequent driver 
aberrations [6, 8, 32]. Although the functional impact 
of this alteration in CLL pathogenesis remains still ill-
defined, its relevance is highlighted by the evidence that 
SF3B1-mutated patients show more aggressive disease and 
shorter survival than unmutated ones. In fact, the presence 
of SF3B1 mutations is associated with disease subtype 
[6, 8], progression [6, 9, 33], chemotherapy resistance 
[9, 14] and overall patient survival [34]. Accordingly, the 
frequency of SF3B1 mutations at diagnosis is around 
5%–7%, and raises up at progression (17%) or after 
treatment (12%–24%) [35]. Recently, gene targeting 
and knockdown experiments collectively have revealed 
that SF3B1 is a proto-oncogene [36, 37], and others have 
proposed that SF3B1 mutations in CLL lead to a defective 
DNA-damage response [38]. It is plausible that SF3B1 
mutations alter features of branch point recognition by the 
SF3B complex. In fact, increased intron retention, alternative 
splicing and activation of cryptic 3′ splice sites were reported 
in CLL samples harboring SF3B1 mutations [6, 8, 39]. 
Additionally, recurrent mutations in other genes of the 
mRNA splicing, processing and transport machinery are also 
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found in CLL [10]. Therefore, the evident relevance of the 
alternative splicing pathway in CLL offers the opportunity 
to design new specific therapeutic strategies targeting the 
spliceosome.
In this article, we tested the antitumor activity of the 
novel splicing modulators sudemycins in CLL primary 
samples. Sudemycins effectively disturb alternative 
splicing in CLL cells, similar to what has been observed 
in other tumor models [20–22]. Our results elucidate for 
the first time that low doses of these compounds induce 
apoptosis in CLL cells, while affecting cell death and 
survival pathways. Intriguingly, CLL cells are exceptionally 
sensitive to the drug when compared with tumor cells from 
other B-lymphoid malignancies, with no alterations in 
SF3B1 reported (MCL, FL and MM), suggesting that this 
pathway is crucial for CLL pathogenesis. In this line, and 
in contrast to normal B cells, CLL cells have increased 
SF3B1 expression [9]. Accordingly, we demonstrated that 
the cytotoxic effect is selective for B-CLL cells, given that 
normal T and B counterparts remain almost unaffected. This 
tumor-selective toxicity is consistent with a model where 
the tumor cells have a deficient regulation of alternative 
Figure 4: NF-κB pathway inhibition by sudemycin. A. Gene expression analysis of NF-κB target genes (IL8, MMP9 and CCL4) by 
quantitative real time PCR. Primary CLL cells from SF3B1-unmutated (n = 5) and mutated (n = 5) cases were incubated with sudemycin D1 
(250 nM) for 6 hours. Gene expression levels are referred to the untreated control sample and represented as the mean ± SEM. *p < 0.05. 
B. SF3B1-unmutated (n = 5) and -mutated (n = 5) CLL samples were stimulated with CD40L (1 μg/mL) and IL4 (20 ng/mL) for 1 hour 
previously to sudemycin D1 incubation. Western blot analysis of p-p65 levels was performed after 6 hours of sudemycin D1 (250 nM) 
exposure (Upper panel). Cytotoxicity was analyzed by flow cytometry at 24 hours (Lower panel). C. Diagram representing alternative 
splicing on RELA exons 7–10 (Upper panel). Representative cases of RT-PCR analysis of spliced and unspliced RELA after CLL cells 
incubation with sudemycin D1 (250 nM) for 6 hours. Primers were designed against exon 7 and 10 from RELA and products were analyzed 
in a QIAxcel capillary electrophoresis device (Lower panel). D. NF-κB p65 activity was determined in SF3B1-unmutated (n = 3) and 
-mutated (n = 4) CLL cases exposed to sudemycin D1 (250 nM) for 6 hours as detailed in “Materials and Methods”.
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Figure 5: Sudemycin and ibrutinib combination in CLL cells. A. Cytotoxicity was analyzed after simultaneous sudemycin 
D1 (100 nM) and ibrutinib (1 μM) exposure for 48 h by annexin V/PI staining. Mean ± SEM of SF3B1-unmutated (n = 8) and -mutated 
(n = 10) cases. *p < 0.05; **p < 0.01. B. Flow cytometry staining of pBtk after exposing SF3B1-unmutated (n = 5) and -mutated (n = 5) CLL 
cells to sudemycin D1 (250 nM) and ibrutinib (1 μM) for 6 hours. Bars represent mean ± SEM. *p < 0.05. C. Diagram representing spliced 
and unspliced IBTK isoforms. Primers were designed against exon 24 and 26 from IBTK. D. Representative cases of RT-PCR analysis of 
spliced and unspliced IBTK after CLL cells incubation with sudemycin D1 (250 nM) for 6 hours. PCR products were analyzed in a QIAxcel 
capillary electrophoresis device.
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splicing, in contrast to normal cells, where this system 
is highly regulated and in consequence, less sensitive to 
spliceosome modulators [40]. Several natural products, their 
derivatives and synthetic analogs that target the spliceosome 
have showed antitumor properties. This effect has been 
related to the ability of these drugs to alter the alternative 
splicing of genes that are relevant for cancer progression 
[30]. In this context, we showed that the apoptotic effect of 
sudemycin might be related to MCL1 alternative splicing, 
similar to what has been described for other spliceosome 
modulators [41, 42]. In CLL, Mcl-1 is a key controller 
of cell survival and correlates with other poor prognostic 
markers [43]. Sudemycin switches the alternative splicing 
of MCL1 toward its proapoptotic short isoform, which 
presumably leads to the induction of the mitochondrial 
apoptotic pathway and the activation of caspase-dependent 
factors. Recently, MCL1-
LONG
 down-regulation rather 
than MCL1-SHORT up-regulation has been postulated to be 
the driver of preferential killing of Mcl-1-dependent cells 
[44]. These authors demonstrated that cytotoxicity can be 
rescued by overexpression MCL1-
LONG
, whereas MCL1-
SHORT overexpression had no significant effect on cells. On 
the other hand, splicing modulators that induced very high 
levels of MCL1-SHORT mRNA in the absence potent MCL1-
LONG
 down-regulation exhibited minimal cytotoxicity [44].
Remarkably, we also demonstrated sudemycin 
efficacy in the in vivo setting, specifically in a NSG mice 
engrafted with peripheral blood cells from CLL patients that 
recapitulates the role of the human lymph node for CLL 
cells [45]. Sudemycin reduces the presence of tumor CLL 
cells in the peripheral blood and spleen of mice both in 
SF3B1-unmutated and -mutated cases though using a very 
low dose, suggesting that sudemycin might target CLL 
cells in their protective niches, where several prosurvival 
pathways are more activated [24]. Among them, NF-κB 
signaling plays a critical role in CLL pathogenesis and 
has become a potential therapeutic target [25]. In this 
context, sudemycin also functionally disturbs NF-κB 
pathway together with the induction of a spliced RELA 
variant that has a diminished DNA-binding ability [26]. 
As a consequence, sudemycin treatment inhibits RELA 
activity, both basal and induced by CD40L-IL4 stimulus, 
and decreases the expression of several target genes related 
to inflammation and tumor invasion, such as IL8, MMP9 
and CCL4. All these results suggest that sudemycin could 
disrupt tumor microenvironment interactions that are often 
related to chemoresistance and disease relapses [46].
Importantly, we also showed for the first time that 
the presence of mutations in SF3B1 or other spliceosome/
RNA processing-related genes confers further sensitivity 
to sudemycin. According to our results, NF-κB pathway 
inhibition might at least partially contribute to these 
differences in sensitivity. While all CLL samples are 
particularly sensitive to the compound, very low doses 
would be enough in mutated cases, probably reflecting an 
accentuated deregulation of the splicing/RNA-processing 
mechanisms in the mutated cells. In this sense, RNA 
sequencing analysis of SF3B1-mutated CLL cases has 
revealed a major disturbance in the splicing fidelity of a large 
number of genes in comparison to -unmutated cases [39, 47].
In CLL, activity and tolerability at clinical level 
of the Btk inhibitor ibrutinib has led to its approval 
and has motivated numerous trials in combination with 
chemotherapy or immunotherapy [27]. In this line, 
spliceosome modulators in combination with this agent 
might be an attractive therapeutic strategy to test in CLL 
patients. Our findings demonstrated for the first time a 
collaborative antitumor effect of sudemycin with the Btk 
inhibitor. Although other splicing events in the components 
of the B-cell receptor pathway might also occur, we 
have demonstrated that Ibtk might play a crucial role 
in the interaction between drugs. Ibtk is an important 
negative regulator of Btk, which leads to inefficient 
autophosphorylation of Btk on residue Y223 when bound 
to the PH domain of Btk, thus inhibiting Btk activity [28]. 
IBTK alternative splicing modulation by sudemycin triggers 
the loss of regulatory function of this protein over Btk, 
consequently upregulating pBtk that is easily overcome 
by ibrutinib addition. Our results suggest that increased 
levels of pBtk after sudemycin exposure could confer 
enhanced sensitivity to ibrutinib. This would be consistent 
with a report where high pBtk levels correlated with major 
sensitivity toward ibrutinib in acute myeloid leukemia [48].
In summary, we show that sudemycin interferes 
in the splicing program of several genes critical for CLL 
survival and apoptosis. Our results confirm that targeting 
the spliceosome in CLL is a promising therapeutic 
strategy, not only for those patients harboring mutations 
in the splicing machinery. Collectively, our study 
provides solid rationale for future clinical development 
of splicesome inhibitors alone or in combination with 
ibrutinib in CLL patients.
MATERIALS AND METHODS
Isolation and culture of primary cells
Primary cells from 41 CLL patients, who were either 
untreated or had not received treatment for the at least 
previous 12 months, were studied (Table 1). Mutations 
in SF3B1 and/or other genes involved in mRNA splicing, 
processing and transport (U2AF2, SFRS2, SRSF7, XPO1, 
NXF1, DDX3X, CPEB3, SMG7, CDCL, HELZ) were 
known from sequencing studies previously reported [6]. 
The IGVH gene mutational status was determined according 
to European Research Initiative on CLL (ERIC) guidelines 
[49]. Percentage of tumor cells (CD19+, CD5+) together 
with cytogenetic alterations were obtained from the clinical 
healthcare activity and assessed by flow cytometry and 
(FISH) respectively, when sampling. Samples from 8 MCL, 
4 FL and 4 MM patients (Supplementary Table S1) and 
5 healthy donors were also studied.
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Primary cells were isolated from PB (for CLL, MCL 
and healthy donors) or bone marrow (BM; for MM) by 
Ficoll-Paque sedimentation (GE Healthcare). Primary FL 
cells were obtained from lymph nodes (LN) after squirting 
with RPMI 1640 (Life Technologies) culture medium 
using a fine needle. Samples were stored within the 
Hematopathology collection of our institution registered 
at the Biobank from Hospital Clínic-IDIBAPS (R121004 
-094). The ethical approval for this project including the 
informed consent of the patients was granted following the 
guidelines of the Hospital Clínic Ethics Committee (IRB).
Cells were cultured in RPMI 1640 supplemented 
with 10% fetal bovine serum (FBS), 2 mM glutamine and 
50 μg/ml penicillin-streptomycin (Life Technologies), in 
a humidified atmosphere at 37ºC containing 5% carbon 
dioxide.
Drug incubation and analysis of apoptosis
Cells were incubated with 100 to 500 nM of 
sudemycin C, D1 or D6 (synthesized and formulated in 
the laboratory of Thomas R. Webb) [22] and/or 1 μM of 
Ibrutinib (Selleck Chemicals) for 30 minutes to 48 hours. 
When specified, cells were preincubated for 1 hour with 10 
μM of the pan-caspase inhibitor Q-VD-OPh (Calbiochem), 
or CD40L (1 μg/mL) and IL4 (20 ng/mL; Sigma-Aldrich). 
Apoptosis was quantified by labeling PS residues exposure 
with annexin V-fluorescein isothiocyanate (FITC) and 
nuclei with propidium iodide (PI; eBioscience). For the 
analysis of apoptosis in CD3+ (T lymphocytes) and CD19+ 
(B lymphocytes) populations, cells were simultaneously 
labeled with anti-CD3-FITC, anti-CD19-Phycoerythrin (PE; 
Becton Dickinson) and annexin V-Pacific Blue (PB; Life 
Technologies). All samples contained > 80% of tumor cells 
except for MM, where tumor cells were co-labeled with 
anti-CD38-PE (Becton Dickinson) and annexin V-FITC, in 
order to gate the population of interest. Caspase-3 activation 
was quantified with CellEvent caspase 3/7 green detection 
reagent (Life Technologies). Ten thousand single cell events 
per sample were acquired in an Attune acoustic cytometer 
(Life Technologies). Cytotoxicity values were obtained after 
relative quantification with each respective control sample 
(without treatment). Untreated control sample represented 
0% of cytotoxicity for each patient’s sample.
RNA splicing analysis by RT-PCR and sanger 
sequencing of splicing isoforms
Total RNA was isolated from 5–10 × 106 CLL 
cells using TRIzol reagent (Life Technologies) according 
to manufacturer’s instructions. cDNA was obtained 
from 0.5–1 μg of DNA-free RNA with the M-MLV 
reverse transcriptase (Life Technologies). Subsequently, 
PCR was run from 2 μl of cDNA with the following 
reaction setup: 1.25 U Amplitaq Gold DNA Polymerase, 
2 mM MgCl2 (Life Technologies), 0.2 mM dNTPs 
(GE Healthcare) and 0.2 μM of each primer; with 
temperature cycling conditions of 94ºC for 5 minutes, 
35 cycles of 94ºC for 30 seconds, 60ºC for 30 seconds 
and 68ºC for 2 minutes, and finally 72ºC for 5 minutes. 
PCR were performed with the following primer pairs: 
5′-GAACCAAAATCACTTTCCCCAAGGAAGG-3′ and 
5′- AATGAGGTCCCCACGTTTCTCGGGTGT-3′ for 
DNAJB1 [16], 5′- GAGGAGGAGGAGGACGAGTT-3′ 
and 5′-ACCAGCTCCTACTCCAGCAA-3′ for MCL1, 
5′-GATGAGATCTTCCTACTGTGTGACAAG-3′ and 
5′-GGGAAGGCACAGCAATGC-3′ for RELA, 
5′-TGTGGATCTCAGAACTATCATGGAA-3′ and 5′- 
GCCTGAACTATGGCTAGTAACAGACTT-3′ for IBTK. 
PCR products were separated in a QIAxcel capillary 
electrophoresis device (QIAgen). For sequencing, 
splicing PCR was performed with the above primers 
harboring an M13 5′-tail and the following conditions: 
95ºC for 10 minutes, 10 cycles of 95ºC for 30 seconds, 
65ºC (decreasing 1ºC each cycle) for 30 seconds and 72ºC 
for 1 minute, 25 cycles of 95ºC for 30 seconds, 55ºC for 
30 seconds and 72ºC for 1 minute, and finally 72ºC for 
7 minutes. PCR products were separated in an agarose gel 
and the candidate product was purified with NucleoSpin 
Gel and PCR Clean-up (Macherey-Nagel). Sequencing 
PCR was performed with the M13 universal primers and 
the BigDye Terminator v1.1 Cycle Sequencing Kit (Life 
Technologies). The experiment was repeated 3 times and 
representative cases are shown.
Protein analysis
Protein extracts were obtained and processed as 
previously described [50]. Membranes were blocked with 
2.5% phosphoBlocker (Cell Biolabs) in Tris-Buffered 
Saline (TBS)-Tween 20. For protein immunodetection, 
the specific primary antibodies were used: Mcl-1, 
phospho(Ser536)-p65 (p-p65; Cell Signaling Technology) 
and β-actin (Sigma-Aldrich). Anti-rabbit and anti-mouse 
horseradish peroxidase-labeled IgG (Sigma-Aldrich) were 
used as secondary antibodies. Chemiluminescence was 
detected with ECL substrate (Pierce Biotechnology) on a 
mini-LAS4000 Fujifilm device (GE Healthcare). Signal 
was quantified with Image Gauge densitometric software 
(Fujifilm) and referred to the respective untreated control.
Nuclear protein extracts and NF-κB p65  
DNA-binding analysis
Cells were incubated with 10 mM pH 7.9, 10 mM 
KCl, 1.5 mM MgCl2, 1 mM DTT supplemented with 
protease inhibitors (0.5 mM phenylmethylsulfonyl 
fluoride, 5 μg/ml aprotinin and 2 μg/ml leupeptin; Sigma-
Aldrich). Lysis was proceeded by adding 0.6% of NP-40. 
Nuclei were pelleted and lysed in 20 mM HEPES pH 7.9, 
0.46 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT 
supplemented as above. Finally, samples were sonicated 
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at high power in a bath sonicator (Diagenode). NF-κB 
p65 activity of 2 μg of nuclear protein was determined 
with the TransAM® NF-κB p65 kit (Active Motif), 
a DNA-binding ELISA coated with oligonucleotides 
containing the NF-κB consensus sequence, according to 
the manufacturer’s protocol. Chemiluminescence was read 
on a mini-LAS4000 Fujifilm device. Signal was quantified 
with Image Gauge densitometric software (Fujifilm) and 
referred to the respective untreated control.
Quantitative real-time PCR
Total RNA was isolated from CLL cells and 
retrotranscribed as above. The following TaqMan Gene 
Expression Assays (Life Technologies) were used: IL8, 
MMP9, CCL4 and ACTB. The relative expression was 
quantified by the comparative cycle threshold (Ct) method 
(ΔΔCt), using ACTB as endogenous control. Expression 
levels are given in arbitrary units, referring to the 
calibrator untreated cells sample.
Phospho-Btk staining
CLL cells were stained with the Live/Dead® Fixable 
Aqua Dead Cell Stain Kit (Life Technologies) and blocked 
with 10% mouse serum (Sigma). Then, samples were 
CD19-FITC labeled and fixed with 1% paraformaldehyde 
(Aname). Cell membrane permeabilization was 
achieved by adding 70% ethanol (Panreac) for 2 hours 
at -20ºC. Intracellular unspecific staining was blocked 
with 10% mouse serum. Finally, cells were stained for 
phospho(Y223)-Btk-PE (pBtk) or mouse IgG1 isotype-
PE (Becton Dickinson) and 10000 viable CLL cells 
were analyzed in an Attune acoustic cytometer (Life 
Technologies). Median Fluorescense Intensity (MFI) of the 
isotype was subtracted to respective pBtk stained sample 
and referred to the corresponding untreated sample.
NSG/CLL mouse xenograft
Sudemycin D6 was tested for in vivo efficacy in an 
adoptive transfer mouse model of CLL, as described by 
Herman et al [45] with modifications. Primary cells from 
CLL patients (50 × 106 per mice; percentage of tumor 
cells: 93–99%) were intravenously inoculated through tail 
vein in six- to eight-week old NSG mice (Charles River 
Laboratories International, Inc), according to a protocol 
approved by the animal testing ethical committee of the 
University of Barcelona (Barcelona, Spain). Six CLL 
cases (n = 3 SF3B1-mutated, n = 3 SF3B1-unmutated) 
were injected in the mice. Each CLL case was injected in 
4 mice (n = 2 control; n = 2 sudemycin). Mice were treated 
intravenously with sudemycin D6 (14 mg/kg) or vehicle 
(10% (2-hydroxypropyl)-β-cyclodextrin in PBS) during 
4 days and sacrificed after 5 days of inoculation. Then, 
spleen and PB samples were recovered and processed 
as previously described [45]. Cell suspensions were 
washed, resuspended with 0.5% BSA in PBS and blocked 
with 10% mouse serum. Samples were incubated with the 
following anti-human antibodies: CD45-Pacific Blue (PB; 
Life Technologies), CD19-PE and CD5-FITC (Becton 
Dickinson) together with PI to assess cell viability. 
The abundance of CLL cells was counted on an Attune 
cytometer as the number of viable CLL cells (CD45+, 
CD19+ and CD5+) per organ (spleen) or per μL (PB).
Statistical analyses
Data are represented as mean ± SEM of all cases. 
Statistics were calculated using GraphPad Prism 4.0 
software (GraphPad Software). Nonparametric Wilcoxon 
signed rank test was used to compare the mean of a set 
of samples to a theoretical value. Comparison between 
two groups of samples was evaluated by non-parametric 
Wilcoxon paired or Mann-Whitney t-test. Results were 
considered statistically significant when p-value < 0.05 
(*p < 0.05, **p < 0.01, ***p < 0.001).
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